肿瘤细胞治疗研究
英文原题：Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.
为了描述利妥昔单抗时代的结果和治疗模式，我们分析了2002年至2022年间在淋巴瘤流行病学结果（LEO）真实世界证据联盟（CReWE）中，344例初诊经活检确认的FL患者，这些患者随后发展为经活检确认的HT。
组织学转化（HT）是滤泡性淋巴瘤（FL）的主要死亡原因，但由于队列规模小且定义异质，其结局仍不明确。为了描述利妥昔单抗时代的结局和治疗模式，我们在淋巴瘤流行病学结局（LEO）真实世界证据联盟（CReWE）中分析了344例2002年至2022年间初始活检确诊为FL、随后发生活检确诊HT的患者。HT时中位年龄为64岁（IQR 57-72）。HT的初始治疗（指数治疗）包括R-CHOP样方案（n=154，45%）和激进/挽救治疗（n=85，25%）。自HT起的中位无事件生存期（EFS）为9个月（95% CI，7-11），2年EFS为30%（95% CI，26%-36%）。自HT起的中位OS为4.9年（95% CI，4.0-7.5），2年和5年OS估计分别为66%（95% CI，61%-71%）和49%（95% CI，43%-56%）。
Histologic transformation (HT) is the leading of death in follicular lymphoma (FL), yet outcomes remain poorly defined due to small cohorts and heterogenous definitions. To characterize outcomes and treatment patterns in the rituximab era we analyzed 344 patients with an initial biopsy-confirmed FL diagnosis between 2002 and 2022 who subsequently developed biopsy-confirmed HT in the Lymphoma Epidemiology of Outcomes (LEO) Consortium of Real-World Evidence (CReWE). Median age at HT was 64 (IQR 57-72). Initial treatment for HT (index therapy) included R-CHOP-like (n=154, 45%) and aggressive/salvage (n=85, 25%). The median event free survival (EFS) from HT was 9 months (95% CI, 7-11), and 2-year EFS was 30% (95% CI, 26%-36%). Median OS from HT was 4.9 years (95% CI, 4.0-7.5) with 2-year and 5-year OS estimates of 66% (95% CI, 61%-71%) and 49% (95% CI, 43%-56%), respectively. Relapses after HT occurred in 60%. Relapse histology included DLBCL 70%, FL 15%, and HGBCL 12%. Treatment following relapse from index therapy was commonly aggressive/salvage (often incorporating ASCT/CAR-T) in 44%. FLIPI (3-5), FL3A histology, IPI (4-5), ECOG >1, diagnosis to HT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
